Ghent University Academic Bibliography

Your filters: cql: author="Grönberg, Henrik" or (type any "bookEditor issueEditor" and editor="Grönberg, Henrik")

Add to list
- Journal Article
- A1
- open access
Prognostic value of the circulating tumor DNA fraction in metastatic castration-resistant prostate cancer : results from the ProBio platform trial

Alessio Crippa, Bram De Laere (UGent) , Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D'hondt (UGent) , Marie Hjälm-Eriksson, Linn Pettersson, Gunilla Enblad, et al.

(2025) EUROPEAN UROLOGY ONCOLOGY. 8(6). p.1486-1495
Add to list
- Journal Article
- A1
- open access
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial

Bram De Laere (UGent) , Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D'hondt (UGent) , Rebecka Bergstrom, Venkatesh Chellappa, Markus Mayrhofer, et al.

(2024) NATURE MEDICINE. 30(11). p.3291-3302
Add to list
- Miscellaneous
- open access
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial (vol 30, pg 3291, 2024)

Bram De Laere (UGent) , Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D'hondt (UGent) , Rebecka Bergstrom, Venkatesh Chellappa, Markus Mayrhofer, et al.

(2024) NATURE MEDICINE. 30(11). p.3381-3381
Add to list
- Journal Article
- A1
- open access
AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Jan Vanwelkenhuyzen (UGent) , Eva Van Bos, Siska Van Bruwaene, Karl Lesage, Alex Maes, Sezgin Üstmert, Filip Lavent, Laurence Beels, Henrik Grönberg, Piet Ost (UGent) , et al.

(2023) EUROPEAN UROLOGY OPEN SCIENCE. 53. p.63-66
Add to list
- Miscellaneous
Discovering fragment length signatures of circulating tumor DNA using Non-negative Matrix Factorization

Gabriel Renaud, Maibritt Nørgaard, Johan Lindberg, Henrik Grönberg, Bram De Laere (UGent) , Jørgen Bjerggaard Jensen, Michael Borre, Claus Lindbjerg Andersen, Karina Dalsgaard Sørensen, Lasse Maretty, et al.

(2021) bioRxiv.
Add to list
- Conference Paper
- C3
Inferring the genomic landscape of lymph-node positive high-risk prostate cancer

Jan Vanwelkenhuyzen (UGent) , Kim Van der Eecken, Bram De Laere (UGent) , Simon Sundling, Rebecka Bergström, Johan Lindberg, Katleen De Preter (UGent) , Henrik Grönberg and Piet Ost (UGent)

(2020) 7th edition of the annual BMUC meeting, Abstracts.
Add to list
- Journal Article
- A1
- open access
The ProBio trial : molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Alessio Crippa, Bram De Laere (UGent) , Andrea Discacciati, Berit Larsson, Jason T. Connor, Erin E. Gabriel, Camilla Thellenberg, Elin Janes, Gunilla Enblad, Anders Ullen, et al.

(2020) TRIALS. 21(1).
Add to list
- Journal Article
- A1
- open access
Has the PROPHECY of AR-V7 been fulfilled?

Bram De Laere, Piet Ost (UGent) , Henrik Gronberg and Johan Lindberg

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(24). p.2181-2182
Add to list
- Journal Article
- A1
- open access
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, et al.

(2019) CLINICAL CANCER RESEARCH. 25(6). p.1766-1773
Add to list
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Bram De Laere, Prabhakar Rajan, Henrik Gronberg, Luc Dirix, Johan Lindberg, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, et al.

(2019) JAMA ONCOLOGY. 5(7). p.1060-1062

Academic Bibliography

Prognostic value of the circulating tumor DNA fraction in metastatic castration-resistant prostate cancer : results from the ProBio platform trial

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial (vol 30, pg 3291, 2024)

AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Discovering fragment length signatures of circulating tumor DNA using Non-negative Matrix Factorization

Inferring the genomic landscape of lymph-node positive high-risk prostate cancer

The ProBio trial : molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Has the PROPHECY of AR-V7 been fulfilled?

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Contents

Support

Contact